JPH053880B2 - - Google Patents
Info
- Publication number
- JPH053880B2 JPH053880B2 JP61500124A JP50012485A JPH053880B2 JP H053880 B2 JPH053880 B2 JP H053880B2 JP 61500124 A JP61500124 A JP 61500124A JP 50012485 A JP50012485 A JP 50012485A JP H053880 B2 JPH053880 B2 JP H053880B2
- Authority
- JP
- Japan
- Prior art keywords
- protease inhibitors
- protease
- administration
- serine protease
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091005804 Peptidases Proteins 0.000 description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
請求の範囲
１ 単一の非断片化ポリペプチド鎖を有し、少な
くとも１種のセリンプロテアーゼのプロテアーゼ
活性を阻害可能であり、次のアミノ酸配列：Claim 1: having a single non-fragmented polypeptide chain, capable of inhibiting the protease activity of at least one serine protease, and having the following amino acid sequence:
【表】
を有する精製セリンプロテアーゼインヒビター。
２ 単一の非断片化ポリペプチド鎖を有し、少な
くとも１種のセリンプロテアーゼのプロテアーゼ
活性を阻害可能であり、次のアミノ酸配列：[Table] Purified serine protease inhibitors. 2 has a single unfragmented polypeptide chain, is capable of inhibiting the protease activity of at least one serine protease, and has the following amino acid sequence:
【表】
を有する精製セリンプロテアーゼインヒビターお
よび医薬的に許容される担体からなる医薬組成
物。
３ 経口投与、非経口投与、局所投与およびエア
ロゾル投与からなる群から選択される経路による
投与に適した形態である請求項２に記載の組成
物。
発明の背景
内因性蛋白分解酵素は、侵入する生物、抗原−
抗体複合体、および生物にとつてもはや必要でな
いかまたは有用でないある種の組織蛋白質を分解
するのに役立つている。正常に機能する生物にお
いて、蛋白分解酵素は、限定された量において導
かれ、そしてプロテアーゼインヒビターの合成を
通して部分的に調節される。
非常に多数の天然に生成するプロテアーゼイン
ヒビターは、内因性プロテアーゼを、局所的およ
び１時間にそれらの反応を限定することにより、
制御するのに役立つている。加えて、プロテアー
ゼインヒビターは、感染剤により身体中に導かれ
るプロテアーゼを阻害しうる。特に蛋白分解性攻
撃および感染を受けやすい組織、たとえば気道の
それはプロテアーゼインヒビターに富んでいる。
プロテアーゼインヒビターは、約A pharmaceutical composition comprising a purified serine protease inhibitor having the following formula and a pharmaceutically acceptable carrier. 3. The composition of claim 2, which is in a form suitable for administration by a route selected from the group consisting of oral administration, parenteral administration, topical administration and aerosol administration. BACKGROUND OF THE INVENTION Endogenous proteolytic enzymes are
It helps break down antibody complexes and certain tissue proteins that are no longer needed or useful to the organism. In normally functioning organisms, proteolytic enzymes are directed in limited amounts and are partially regulated through the synthesis of protease inhibitors. A large number of naturally occurring protease inhibitors inhibit endogenous proteases by limiting their response locally and to one hour.
It's helpful to control. In addition, protease inhibitors can inhibit proteases that are introduced into the body by infectious agents. Tissues that are particularly susceptible to proteolytic attack and infection, such as those of the respiratory tract, are rich in protease inhibitors. Protease inhibitors are approximately
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67882384A | 1984-12-06 | 1984-12-06 | |
| US678823 | 1991-04-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62501291A JPS62501291A (en) | 1987-05-21 |
| JPH053880B2 true JPH053880B2 (en) | 1993-01-18 |
Family
ID=24724432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61500124A Granted JPS62501291A (en) | 1984-12-06 | 1985-12-04 | Purified serine protease inhibitor and pharmaceutical composition containing same |
| JP4166079A Expired - Lifetime JPH0717678B2 (en) | 1984-12-06 | 1992-06-24 | Serine protease inhibitor and pharmaceutical composition containing the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4166079A Expired - Lifetime JPH0717678B2 (en) | 1984-12-06 | 1992-06-24 | Serine protease inhibitor and pharmaceutical composition containing the same |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JPS62501291A (en) |
| ZA (1) | ZA859362B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600571A1 (en) * | 1986-01-10 | 1987-08-06 | Gruenenthal Gmbh | DNA SEQUENCES CODING FOR PROTEINS WITH THE BIOLOGICAL ACTIVITY OF HUSI-TYPI INHIBITORS, GENE-TECHNOLOGICAL METHODS FOR THE PRODUCTION OF THESE PROTEINS AND MEDICINAL PRODUCTS CONTAINING THESE PROTEINS |
| FI963753L (en) * | 1994-03-23 | 1996-09-20 | Tokyo Tanabe Co | New drug to treat respiratory viral disease |
| AU6530696A (en) * | 1995-07-24 | 1997-02-18 | Tokyo Tanabe Company Limited | Remedy for viral diseases |
-
1985
- 1985-12-04 JP JP61500124A patent/JPS62501291A/en active Granted
- 1985-12-06 ZA ZA859362A patent/ZA859362B/en unknown
-
1992
- 1992-06-24 JP JP4166079A patent/JPH0717678B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62501291A (en) | 1987-05-21 |
| JPH05208999A (en) | 1993-08-20 |
| JPH0717678B2 (en) | 1995-03-01 |
| ZA859362B (en) | 1987-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6287840B1 (en) | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups | |
| CA2030433A1 (en) | New isoquinoline- carboxamide amino acid derivatives useful for treatment of viral diseases | |
| US5444042A (en) | Method of treatment of neurodegeneration with calpain inhibitors | |
| HUP0400732A2 (en) | Pharmaceutically active uridine esters | |
| WO2002018369A3 (en) | Peptidomimetic protease inhibitors | |
| IL129238A0 (en) | N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds | |
| CA2098609A1 (en) | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration | |
| TR200101120T2 (en) | Serine protease inhibitor | |
| PL349334A1 (en) | Therapeutic agent for the suppression of snoring noises | |
| MY132473A (en) | Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman | |
| MY139203A (en) | Pharmaceutical composition | |
| DE60008399D1 (en) | CARBONIC ACIDS AND ACYLSULFONAMIDES, PREPARATIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHODS | |
| IL111673A (en) | 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them | |
| ES8802468A1 (en) | Bone targeted inhibitors of carbonic anhydrase. | |
| EP1019047A4 (en) | Antithrombotic agents | |
| JPH053880B2 (en) | ||
| WO2002064552A8 (en) | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | |
| CA2221793A1 (en) | Novel antibacterial protein | |
| RU94040865A (en) | Peptide derivatives and therapeutically acceptable salts thereof, process for preparation thereof, pharmaceutical composition having antiviral activity | |
| JP3193085B2 (en) | Method for producing composition containing angiotensin converting enzyme inhibitor | |
| EP1027051A4 (en) | Antithrombotic agents | |
| ATE103178T1 (en) | T-PA PRO STABILIZATION. | |
| NZ256246A (en) | Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection | |
| US7067476B2 (en) | Peptide derivative, and pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | |
| CA2190952A1 (en) | Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection |